US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Binah Capital Group Inc

2.18

+0.01030.47%

Volume:803.00

Turnover:1.77K

Market Cap:36.20M

PE:-6.84

High:2.22

Open:2.22

Low:2.18

Close:2.17

Loading ...

Overview Company News Filings

Press Release: JLL announces senior leadership appointments

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Binah Capital Group Inc. Appoints Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer, Signaling Strategic Growth Expansion

Binah Capital Group Expands Executive Team With Appointment of Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer

THOMSON REUTERS

Press Release: Binah Capital Group Expands Executive Team with Appointment of Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer

Buy Rating for CG Oncology, Inc. Driven by Cretostimogene’s Potential in Bladder Cancer Treatment Amid BCG Shortage

Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Press Release: Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCG/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCG\",,,,,undefined,":{"symbol":"BCG","market":"US","secType":"STK","nameCN":"Binah Capital Group Inc","latestPrice":2.1803,"timestamp":1747060042005,"preClose":2.17,"halted":0,"volume":803,"delay":0,"floatShares":3144502,"shares":16602460,"eps":-0.318929,"marketStatus":"Trading","change":0.0103,"latestTime":"05-12 10:30:14 EDT","open":2.22,"high":2.22,"low":2.1803,"amount":1768.2616478999998,"amplitude":0.018295,"askPrice":2.2,"askSize":300,"bidPrice":2.18,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.318929,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1747080000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":2.17,"postHourTrading":{"tag":"盘后","latestPrice":2.17,"preClose":2.17,"latestTime":"16:46 EDT","volume":50,"amount":108.5,"timestamp":1746823582683},"volumeRatio":0.219238},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCG\",,,,,undefined,":{"symbol":"BCG","floatShares":3144502,"roa":"-6.80%","roe":"-42.87%","lyrEps":-0.318929,"volumeRatio":0.219238,"shares":16602460,"dividePrice":0,"high":2.22,"amplitude":0.018295,"preClose":2.17,"low":2.1803,"week52Low":1.71,"pbRate":"-134.57","psRate":"0.22","week52High":12.22,"institutionHeld":0,"latestPrice":2.1803,"committee":-0.2,"eps":-0.318929,"divideRate":0,"volume":803,"delay":0,"ttmEps":-0.318929,"open":2.22,"prevYearClose":2.94,"prevWeekClose":2.17,"prevMonthClose":2.27,"prevQuarterClose":1.93,"fiveDayClose":2.2,"twentyDayClose":2.07,"sixtyDayClose":2.08},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCG\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533998945","title":"Press Release: JLL announces senior leadership appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2533998945","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533998945?lang=en_us&edition=fundamental","pubTime":"2025-05-07 19:36","pubTimestamp":1746617760,"startTime":"0","endTime":"0","summary":"Karen Brennan appointed Chief Executive Officer of Leasing Advisory business globally. Kelly Howe to serve as next Chief Financial Officer of JLL. CHICAGO, May 7, 2025 /PRNewswire/ -- JLL today announced the following senior leadership appointments, effective July 1, 2025.Karen Brennan, who has served for the past five years as the company's Chief Financial Officer and sits on JLL's Global Executive Board, has been appointed as Chief Executive Officer of JLL's Leasing Advisory business globally.Christian Ulbrich, President and CEO of JLL, said, \"Throughout Karen's more than 25 year tenure at JLL she has taken on numerous leadership roles across the business globally, and exemplified strategic vision, excellence in execution and dedication to our clients. This appointment recognizes the contributions Karen has made to JLL's success, and our confidence in her ability to drive continued value for the stakeholders we serve.\". During the course of her more than 25 years of experience, Karen","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4079","BK6039","BCG","JLL","BK6520","BK4135","LU0054578231.USD","NEX.SI"],"gpt_icon":0},{"id":"2533585058","title":"Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533585058","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533585058?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:49","pubTimestamp":1746445740,"startTime":"0","endTime":"0","summary":"The U.S. FDA has approved SELARSDI  as interchangeable with the reference biologic Stelara  in all presentations matching the reference product, effective as of April 30, 2025. SELARSDI is approved for all indications matching the reference product. SELARSDI is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older, and the treatment of adult patients with moderately to severely active Crohn’s disease and ulcerative colitis. PARSIPPANY, N.J. & REYKJAVK, Iceland, May 05, 2025  -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , and Alvotech  today announced that the U.S. Food and Drug Administration  has approved SELARSDI  injection as interchangeable with the reference biologic Stelara . As of April 30, 2025, SELARSDI is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic art","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/teva-alvotech-announce-fda-approval-114900298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4099","BK4171","BK4574","F","TEVA","ALVOW","FR","BK4156","BK4588","BCG","BK4135","BK4516","ALVO","BK4555","BK4585","BK4139","BK4224"],"gpt_icon":0},{"id":"2532076959","title":"Binah Capital Group Inc. Appoints Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer, Signaling Strategic Growth Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2532076959","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532076959?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:38","pubTimestamp":1746099515,"startTime":"0","endTime":"0","summary":"Binah Capital Group Inc. Appoints Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer, Signaling Strategic Growth Expansion. Binah Capital Group Inc. announced the appointment of Ryan Marcus as Chief Business Development and Engagement Officer. Marcus will collaborate with Binah Capital's broker-dealers to develop and implement long-term business strategies, aiming to enhance market presence and drive sustainable growth. His experience in strategic growth execution and wealth management is expected to contribute significantly to the company's objectives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Binah Capital Group Inc. published the original content used to generate this news brief via GlobeNewswire ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL5gbpCs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BKPKM429.USD","BK4585","IE00BGHQF748.EUR","BK4112","NDAQ","BK4588","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4135","LU2095319765.USD","BCG"],"gpt_icon":0},{"id":"2532839076","title":"Binah Capital Group Expands Executive Team With Appointment of Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2532839076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532839076?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:38","pubTimestamp":1746099482,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nTUABDFVLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCG","BK4135"],"gpt_icon":0},{"id":"2532075023","title":"Press Release: Binah Capital Group Expands Executive Team with Appointment of Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2532075023","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532075023?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:38","pubTimestamp":1746099480,"startTime":"0","endTime":"0","summary":"Binah Capital Group Expands Executive Team with Appointment of Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer. In his new role, Mr. Marcus will work closely with Binah Capital's broker-dealers, including PKS Investments, Cabot Lodge Securities and World Equity Group, to develop and implement long-term business strategies. He will focus on enhancing market presence, building a unified value proposition and driving sustainable growth across the organization.\"Ryan is a rare talent and industry builder who understands how trust, transparency and long-term value are created and maintained,\" said Craig Gould, CEO of Binah Capital Group. \"His deep relationships and intuitive grasp of the advisor landscape will strengthen our ability to deliver unparalleled support to our partners. We're thrilled to welcome him as a senior executive at Binah and look forward to working together to execute on our strategic growth plans.\". Binah Capital Group (\"Binah Capital\", ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","BK4108","TISI","MCS","BK4135","BCG"],"gpt_icon":0},{"id":"2531733861","title":"Buy Rating for CG Oncology, Inc. Driven by Cretostimogene’s Potential in Bladder Cancer Treatment Amid BCG Shortage","url":"https://stock-news.laohu8.com/highlight/detail?id=2531733861","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531733861?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:15","pubTimestamp":1745928946,"startTime":"0","endTime":"0","summary":"Analyst Alec Stranahan of Bank of America Securities maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-inc-driven-by-cretostimogenes-potential-in-bladder-cancer-treatment-amid-bcg-shortage?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-inc-driven-by-cretostimogenes-potential-in-bladder-cancer-treatment-amid-bcg-shortage?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CG","CGON","BCG"],"gpt_icon":0},{"id":"2531869477","title":"Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware","url":"https://stock-news.laohu8.com/highlight/detail?id=2531869477","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531869477?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:45","pubTimestamp":1745923500,"startTime":"0","endTime":"0","summary":"Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA. RAHWAY, N.J., April 29, 2025----Merck , known as MSD outside of the United States and Canada, announced today the start of construction for a $1 billion, 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, Delaware.A cornerstone of Merck’s continued commitment to investing in American innovation and infrastructure, Merck Wilmington Biotech will comprise laboratory, manufacturing and warehouse capabilities to enable the launch and commercial production of next-generation biologics and therapies including potent antibody-drug conjugates , reinforcing Merck’s focus on expanding and diversifying its pipeline.With proximity to Delaware and Pennsylvania universities, Merck Wilmington Biotech will also attract talented students and professionals, supporting community growth and development. The site’s proximity to Merck’s existing facilities ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-breaks-ground-1-billion-104500898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","BK4135","BK4559","LU0320765646.SGD","LU1291159041.SGD","MRK","LU1023059063.AUD","LU1069347547.HKD","BTC","LU0208291251.USD","BK4585","LU2324357040.USD","BK4161","LU2361045086.USD","SG9999002224.SGD","LU1585245621.USD","LU1116320901.HKD","LU1983299246.USD","ALT","LU0965509283.SGD","LU1066051498.USD","LU2468319806.SGD","BK4533","SG9999015341.SGD","CRT","LU0861579265.USD","LU0122379950.USD","LU0965508806.USD","LU0965509010.AUD","LU1116320737.USD","LU1929549753.HKD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1066051811.HKD","LU2023250504.SGD","RCC","LU1974910355.USD","CPS","LU0265550946.USD","IE00B4R5TH58.HKD","LU1035773651.USD","LU0211331839.USD","LU1066053197.SGD","SG9999001440.SGD","BCG","HSCT","HCC","DM","CRC","BK4588"],"gpt_icon":0},{"id":"2531816437","title":"Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2531816437","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531816437?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:45","pubTimestamp":1745923500,"startTime":"0","endTime":"0","summary":"Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment. NEW YORK, April 29, 2025----Pfizer Inc.  reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance.\"Our overall solid first-quarter performance demonstrates our continued focus on commercial execution amid U.S. Medicare Part D headwinds. Our focus on operational efficiency and financial discipline is driving strong results to our bottom line. We are currently trending towards the upper end of our 2025 Adjusted diluted EPS guidance range.\". First-Quarter 2025 Revenues of $13.7 Billion, Reported Diluted EPS of $0.52, and Adjusted Diluted EPS of $0.92. On Track to Deliver Operating Margin Expansion from Ongoing Cost Realignment Program with Approximately $4.5 Billion of Net Cost Savings by End of 2025, and Announces Additional Productivity Gains Expected Through 2027 Leveraging Digital Enablement and Process Simplification. First Phase of Manufacturing Optimizatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-reports-solid-first-quarter-104500122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999002224.SGD","LU1066051498.USD","LU0054578231.USD","BK4213","LU0321505439.SGD","BK4195","BNTX","LU1057294990.SGD","LU0058720904.USD","OS","PFS","ITT","LU0868494617.USD","PFE","BK4534","LU1894683264.USD","BK4568","LU0321505868.SGD","IE0002270589.USD","IE00B19Z3581.USD","SG9999002232.USD","SOC","BK4230","LU0234572021.USD","BK4599","LU0225771236.USD","BK4022","CAR","LU0289739699.SGD","LU0170899867.USD","LU1894683348.USD","IE000M9KFDE8.USD","LU1066053197.SGD","EC","BK4581","BK4585","BCG","BK4533","IE00BLSP4452.SGD","CDC","SGXZ57979304.SGD","LU0225284248.USD","LU0053671581.USD","LU0122379950.USD","BK4535","BK4548","BK4135","BK4550","SG9999013999.USD"],"gpt_icon":1},{"id":"2531912232","title":"CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2531912232","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531912232?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:14","pubTimestamp":1745853277,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc.  announced on Saturday that cretostimogene grenadenorepvec monotherapy data were presented at the 2025 American Urological Association Annual Meeting.The Phase 3 BOND-003 Cohort C study is in patients with high-risk non-muscle invasive bladder cancer  unresponsive to Bacillus Calmette Guerin  treatment with carcinoma in situ  with or without Ta or T1 disease.The study reported 75.5% complete response  at any time, with 34 confirmed CRs at 24 months and nine patients pending their 24-month assessment as of the March 14, 2025, cutoff date.Also Read: ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug. The 12—and 24-month CR rates are 50.7% and 42.3%, respectively, by K-M estimation.The median duration of response  is 28 months and ongoing. Notably, 97.3% of patients were free from progression to muscle-invasive disease at 24 months.Additionally, Cohort P, in patients with BCG-unresponsive Ta/T1 disease without CIS, showed an estimated 90.5% high-grade r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncologys-bladder-cancer-drug-151437058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CGON","ISBC","IE00B3QW5Z07.USD","BK4161","BK4211","CR","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","CG","BK4135","BCG"],"gpt_icon":0},{"id":"2530548354","title":"KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530548354","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530548354?lang=en_us&edition=fundamental","pubTime":"2025-04-28 00:00","pubTimestamp":1745769600,"startTime":"0","endTime":"0","summary":"KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma . Results to be presented at American Association for Cancer Research  Annual Meeting 2025 during a Plenary Session and included in official meeting press program. \"As the first positive trial in over two decades for patients with resectable, locally advanced head and neck squamous cell carcinoma, the presentation of these landmark results marks an important moment for these patients and those who care for them,\" said Dr. Ravindra Uppaluri, the study’s co-principal investigator, director of Head and Neck Surgical Oncology, Brigham and Women’s Hospital and Dana-Farber","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keytruda-pembrolizumab-perioperative-treatment-standard-160000135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2023250843.SGD","BK4161","ON","CRT","SMP","HSCT","DM","SOC","LU1162221912.USD","CRC","LU2361044865.SGD","IE00BZ199S13.USD","BTC","LU2361044949.HKD","BCG","AEIS","IE00B7SZL793.SGD","BK4097","LU1854103824.USD","CPS","LU0320765646.SGD","BK4605","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU1861220033.SGD","LU2298322129.HKD","SG9999014567.USD","LU0289739699.SGD","LU0320765489.SGD","LU1934455194.USD","LU0861579265.USD","LU0208291251.USD","SG9999015358.SGD","HCC","BK4135","LU0054578231.USD","LU1066051225.USD","LU2106854487.HKD","SGXZ57979304.SGD","IE0009355771.USD","RCC","LU1037948541.HKD","LU0265550946.USD","MRK","ALT","LU1430594728.SGD","OS","SG9999001440.SGD","ITT","BK4533"],"gpt_icon":0},{"id":"2530171196","title":"CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530171196","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530171196?lang=en_us&edition=fundamental","pubTime":"2025-04-27 04:10","pubTimestamp":1745698200,"startTime":"0","endTime":"0","summary":"- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C –。- 58.3% of patients showed durable complete responses by K-M at 24 months –。- 97.3% of all treated patients remained free from progression to MIBC at 24 months–。- 91.6% of responders remained cystectomy-free at 24 months –。- No Grade 3 or greater treatment-related adverse events or deaths reported –。- Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M –。- Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 -. IRVINE, Calif., April 26, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that cretostimogene grenadenorepvec monotherapy data was presented at the Practice-Changing, Paradigm-Shifting Clinical Trials in Urology Plen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-announces-best-disease-201000079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4139","BK4585","US6M.BOND","BK4588","US3Y.BOND","US7Y.BOND","US10Y.BOND","AFG","CGON","IE00B64PRP62.GBP","US12M.BOND","BK4117","BK4161","US5Y.BOND","CR","BOND","BCG","US30Y.BOND","CG","BK4107","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","US2Y.BOND"],"gpt_icon":0},{"id":"2530175941","title":"Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175941","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175941?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:50","pubTimestamp":1745689800,"startTime":"0","endTime":"0","summary":"Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response  with more than half of responders remaining cancer-free at one year after CR. Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer. As of March 2025, 82.4 percent of the 85 enrolled patients in the study achieved a complete response  , meaning their cancer was undetectable following treatment. This high response rate translated into sustained disease control, with 52.9 percent of responders maintaining complete response at one year. The median duration of response  was 25.8 months , indicating that many patients remained cancer-free for over two years without the need for reinduction therapy. At 12 months, 86.6 perc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-175000318.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-175000318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2505996509.AUD","LU1061106388.HKD","CR","IE00BDGV0183.EUR","JNJ","LU1032955483.USD","LU0912757837.SGD","RC","LU1059921491.USD","OS","LU0234570918.USD","LU2468319806.SGD","LU2430703178.SGD","LU2592432038.USD","IE000M9KFDE8.USD","IE00BFTCPJ56.SGD","LU0795875086.SGD","LU1066051811.HKD","LU1244550494.USD","LU1929549753.HKD","IE00B19Z3B42.SGD","LU0466842654.USD","IE00BN8TJ469.HKD","LU0882574055.USD","IE00B7SZLL34.SGD","LU0114720955.EUR","LU1221951046.USD","LU1674673691.USD","BK4504","LU1244550221.USD","LU1718418525.SGD","LU1244550577.SGD","IE00BLSP4239.USD","LU1074936037.SGD","LU2347655156.SGD","SG9999002232.USD","LU0792757196.USD","LU1914381329.SGD","LU1894683264.USD","IE00B2B36J28.USD","LU0345769128.USD","BCG","LU0203347892.USD","BK4533","LU2129689431.USD","LU2089984988.USD","LU0345769631.USD","IE00B1BXHZ80.USD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2530175929","title":"Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175929","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175929?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:30","pubTimestamp":1745688600,"startTime":"0","endTime":"0","summary":"Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care  Bacillus Calmette-Guérin  regimen compared to SOC alone. Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-nave, high-risk non-muscle invasive bladder cancer in more than 30 years. Results have been shared with global health authorities to support potential regulatory filings. \"New bladder cancer treatment options that help reduce rates of disease recurrence or progression are long overdue. Up to 50% of patients with high-risk non-muscle invasive bladder cancer may experience failure of BCG intravesical immunotherapy, yet it has been the standard of care after tumor resection for decades,\" said Neal Shore, M.D., FACS, Medical Director for START Carolina Research Center, and lead investigator ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-sasanlimab-combination-significantly-improves-173000786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999002224.SGD","LU0321505439.SGD","BK4213","LU1057294990.SGD","LU0985481810.HKD","OS","SG9999011175.SGD","CI","PFE","BK4592","BK4534","BK4097","BK4588","IE0002270589.USD","LU1059921491.USD","BK4007","ADC","SG9999002232.USD","SOC","LU0234572021.USD","LU0225771236.USD","LU1261432733.SGD","IE00BBT3K403.USD","LU0289739699.SGD","LU0170899867.USD","IE00BSNM7G36.USD","HR","IE000M9KFDE8.USD","LU1066053197.SGD","BK4581","BK4585","BCG","BK4231","BK4533","BK4203","SGXZ57979304.SGD","LU1023059063.AUD","LU1883839398.USD","LU0306806265.USD","CR","IE00BLSP4239.USD","LU0122379950.USD","LU0456855351.SGD","SG9999003800.SGD","BK4550","BK4135","SG9999001176.USD","SG9999013999.USD","LU1894683348.USD"],"gpt_icon":1},{"id":"2529986685","title":"CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529986685","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529986685?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., April 24, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer  to be presented on April 26, 2025, at a Plenary Session at the American Urological Association  Annual Meeting in Las Vegas, Nevada.About Bladder CancerMore than 85,000 people are estimated to be diagnosed with bladder cancer in 2025. NMIBC is the most common form of bladder cancer, representing approximately 75% of newly diagnosed cases. Bladder cancer is the sixth most common form of cancer in the United States, and men account for three quarters of newly diagnosed cases.Cretostimogene is an investigational, intravesical","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-host-conference-call-120000320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CGON","BK4588","CG","US6M.BOND","US10Y.BOND","BK4218","BCG","US30Y.BOND","US3Y.BOND","US2Y.BOND","US7Y.BOND","IE00BGHQF748.EUR","BK4139","BOND","IE00B3QW5Z07.USD","BK4585","US12M.BOND","BK4135","IE00B64PRP62.GBP","HST","BK4181","US5Y.BOND"],"gpt_icon":0},{"id":"2529502826","title":"Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529502826","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529502826?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409600,"startTime":"0","endTime":"0","summary":"NEW YORK, April 23, 2025  -- Protara Therapeutics, Inc., a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025, to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer , including data from patients who have reached the 12-month evaluation timepoint. The data will be featured during an interactive poster session at the American Urological Association 2025 Annual Meeting on Saturday, April 26, 2025, at 7:00 a.m. PT.TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and of LMs, for which it has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protara-therapeutics-host-conference-call-120000732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCG","BK4218","TARA","AEIS","IE00B66KJ199.SGD","IE00B7SZL793.SGD","IFN","IE0031619046.USD","BK4585","BK4588","BK4181","HST","BK4157","BK4523","BK4135","IE00B19Z4B17.USD","BK4139"],"gpt_icon":0},{"id":"2527042761","title":"Press Release: Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527042761","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527042761?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:13","pubTimestamp":1744747980,"startTime":"0","endTime":"0","summary":"NEW YORK, April 15, 2025  -- Protara Therapeutics, Inc. , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies.\"We are delighted to welcome Dr. Nicacio to the Protara team,\" said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. \"As a proven leader with deep expertise spanning all stages of drug development, his guidance and insight will be invaluable as we advance our therapeutic candidates for patients impacted by some of the most underserved cancers and rare diseases.\". Dr. Nicacio earned his Medical Degree from Faculdade de Ciencias Medicas de Minas Gerais and completed a molecular biology research fellowship at New York Blood Center. He is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","BK4007","BK4139","BK4135","LENZ","BCG"],"gpt_icon":0},{"id":"2527413421","title":"ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2527413421","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527413421?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"Company to Provide Regulatory, Sales, and Platform Updates at Investor Day including:. In Q1, the company submitted a supplemental Biologics License Application  for use of ANKTIVA plus Bacillus Calmette-Guérin  in BCG-unresponsive non-muscle invasive bladder cancer  for the indication of papillary disease.In Q2, the company submitted to the U.S. Food and Drug Administration  an Expanded Access Protocol  for ANKTIVA for the treatment of lymphopenia as a BioShield against the adverse effects of chemotherapy, radiation and checkpoint inhibitors, following authorization of a Regenerative Medicine Advanced Therapy  designation for this indication in Q1.With a permanent J-code  awarded in January 2025, ImmunityBio’s Q1 2025 ANKTIVA unit sales volume grew 150% over unit sales volume in Q4 2024.CULVER CITY, Calif., April 15, 2025----ImmunityBio, Inc. , a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunitybio-announces-fda-submissions-supplemental-120000240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","BK4585","BK4139","BK4588","DFS","LU1861220207.SGD","CARE","LU1791807156.HKD","BK4166","LU1668664300.SGD","BCG","LU0106831901.USD","LU1861217088.USD","IBRX","BK4135","LU2360107671.USD"],"gpt_icon":0},{"id":"2526954081","title":"Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526954081","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526954081?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:05","pubTimestamp":1744315500,"startTime":"0","endTime":"0","summary":"NEW YORK, April 10, 2025  -- Protara Therapeutics, Inc., a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announcedthat two presentations and a panel discussion highlighting the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer  will be featured at the upcoming American Urological Association  2025 Annual Meeting taking place fromApril 26, 2025to April 29, 2025 inLas Vegas.A copy of the abstract for the ADVANCED-2 interim analysis is now available on the AUA website. Updated safety and efficacy data, including data from patients who have reached the 12-month evaluation timepoint, will be featured during an interactive poster session on Saturday, April 26, 2025.ADVANCED-2  is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS  who are Bacillus Calmette-Guérin -unresponsive  and BCG-Nave . The BCG-Unresponsive c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protara-therapeutics-present-interim-analysis-200500382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TARA","AFG","BK4135","IE00B19Z4B17.USD","BK4157","IE00B66KJ199.SGD","BK4117","IE00B7SZL793.SGD","IE0031619046.USD","BCG","BK4139","BK4523","IFN","AEIS","BK4107"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":119,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCG\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCG\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCG","date":"2025-05-09","current":-7.860875,"percent":0.72549,"low":-94.684933,"twenty":-18.572243,"median":-9.867391,"eighty":-7.314981,"high":216.897522,"avg":3.216997,"sd":59.084226,"marketCap":35861313},"quantilePoints":[{"date":"2024-04-12","current":47.846282,"twenty":47.314657,"median":50.799756,"eighty":52.276493,"marketCap":133339024},{"date":"2024-04-19","current":40.132439,"twenty":41.297957,"median":46.73873,"eighty":50.917895,"marketCap":111841925},{"date":"2024-04-26","current":203.935518,"twenty":44.420253,"median":50.799756,"eighty":187.977853,"marketCap":116447181},{"date":"2024-05-03","current":181.468046,"twenty":45.542573,"median":118.644354,"eighty":199.211588,"marketCap":103618254},{"date":"2024-05-10","current":158.424485,"twenty":47.403261,"median":158.424485,"eighty":194.026786,"marketCap":90460381},{"date":"2024-05-17","current":135.380923,"twenty":48.08256,"median":150.76106,"eighty":191.347973,"marketCap":77302507},{"date":"2024-05-24","current":216.897522,"twenty":50.268131,"median":142.815352,"eighty":191.347973,"marketCap":123848485},{"date":"2024-05-31","current":-70.098677,"twenty":46.96024,"median":139.70159,"eighty":188.726768,"marketCap":145945446},{"date":"2024-06-07","current":-77.180156,"twenty":40.710114,"median":130.655552,"eighty":184.646906,"marketCap":160689084},{"date":"2024-06-14","current":-52.991736,"twenty":-57.718026,"median":121.266741,"eighty":182.34255,"marketCap":110328794},{"date":"2024-06-21","current":-39.863152,"twenty":-52.943996,"median":66.796341,"eighty":180.865278,"marketCap":82995083},{"date":"2024-06-28","current":-46.865063,"twenty":-56.142596,"median":53.605557,"eighty":179.659743,"marketCap":97573062},{"date":"2024-07-05","current":-45.194153,"twenty":-52.896255,"median":49.470693,"eighty":176.203209,"marketCap":94094226},{"date":"2024-07-12","current":-42.966272,"twenty":-51.448132,"median":45.631177,"eighty":169.370177,"marketCap":89455779},{"date":"2024-07-15","current":-46.626362,"twenty":-50.795682,"median":45.409667,"eighty":167.641909,"marketCap":97076086},{"date":"2024-08-02","current":-31.986002,"twenty":-50.143231,"median":45.188156,"eighty":165.913642,"marketCap":66594857},{"date":"2024-08-09","current":-28.166778,"twenty":-49.363473,"median":40.613835,"eighty":159.576663,"marketCap":58643232},{"date":"2024-08-16","current":-20.272151,"twenty":-47.35838,"median":-24.029285,"eighty":158.424485,"marketCap":59802844},{"date":"2024-08-23","current":-19.247598,"twenty":-46.674102,"median":-19.602159,"eighty":156.120128,"marketCap":56780413},{"date":"2024-08-30","current":-19.866672,"twenty":-46.24444,"median":-19.585275,"eighty":147.891273,"marketCap":58606683},{"date":"2024-09-06","current":-18.302664,"twenty":-45.957998,"median":-19.585275,"eighty":144.080444,"marketCap":53992860},{"date":"2024-09-13","current":-15.251751,"twenty":-45.448768,"median":-19.106899,"eighty":140.947095,"marketCap":44992666},{"date":"2024-09-20","current":-16.883858,"twenty":-45.194153,"median":-18.403405,"eighty":138.834001,"marketCap":49807380},{"date":"2024-09-27","current":-18.009448,"twenty":-45.194153,"median":-18.156337,"eighty":136.530797,"marketCap":53127872},{"date":"2024-10-04","current":-14.801515,"twenty":-45.098673,"median":-18.009448,"eighty":129.710478,"marketCap":43664469},{"date":"2024-10-11","current":-15.139192,"twenty":-44.271652,"median":-17.794742,"eighty":123.304944,"marketCap":44660617},{"date":"2024-10-18","current":-13.732204,"twenty":-43.642912,"median":-16.883858,"eighty":121.209133,"marketCap":40510002},{"date":"2024-10-25","current":-11.706141,"twenty":-43.204974,"median":-16.377341,"eighty":95.05469,"marketCap":34533116},{"date":"2024-10-31","current":-12.147373,"twenty":-41.725024,"median":-16.067805,"eighty":68.991477,"marketCap":35834749},{"date":"2024-11-08","current":-12.325216,"twenty":-38.781038,"median":-15.870826,"eighty":54.048578,"marketCap":36359387},{"date":"2024-11-15","current":-19.641554,"twenty":-35.089122,"median":-15.983385,"eighty":51.154173,"marketCap":57942585},{"date":"2024-11-22","current":-9.482521,"twenty":-31.222157,"median":-15.814546,"eighty":49.736506,"marketCap":41174100},{"date":"2024-11-29","current":-9.867391,"twenty":-29.805862,"median":-15.758267,"eighty":48.08256,"marketCap":42834346},{"date":"2024-12-06","current":-9.217214,"twenty":-28.707835,"median":-15.561288,"eighty":47.403261,"marketCap":40011928},{"date":"2024-12-13","current":-11.205991,"twenty":-28.548701,"median":-15.251751,"eighty":45.542573,"marketCap":48645207},{"date":"2024-12-20","current":-8.873003,"twenty":-28.103124,"median":-15.039858,"eighty":44.420253,"marketCap":38517707},{"date":"2024-12-27","current":-11.66494,"twenty":-27.84851,"median":-14.773376,"eighty":41.348639,"marketCap":50637503},{"date":"2025-01-03","current":-10.555814,"twenty":-27.84851,"median":-14.407558,"eighty":41.145913,"marketCap":45822789},{"date":"2025-01-10","current":-10.364586,"twenty":-27.132405,"median":-13.712083,"eighty":40.517556,"marketCap":44992666},{"date":"2025-01-17","current":-9.599672,"twenty":-25.795677,"median":-13.338247,"eighty":11.509386,"marketCap":41672174},{"date":"2025-01-24","current":-9.561426,"twenty":-24.74539,"median":-12.325216,"eighty":-7.572649,"marketCap":41506150},{"date":"2025-01-31","current":-8.069843,"twenty":-22.526431,"median":-12.059139,"eighty":-7.572649,"marketCap":35031190},{"date":"2025-02-07","current":-8.299318,"twenty":-20.109959,"median":-11.84684,"eighty":-7.649141,"marketCap":36027338},{"date":"2025-02-14","current":-7.955106,"twenty":-19.799137,"median":-11.755302,"eighty":-7.809773,"marketCap":34533116},{"date":"2025-02-21","current":-7.534404,"twenty":-19.697834,"median":-11.685541,"eighty":-7.672088,"marketCap":32706846},{"date":"2025-02-28","current":-10.976517,"twenty":-19.697834,"median":-11.593582,"eighty":-7.542053,"marketCap":47649060},{"date":"2025-03-07","current":-8.567038,"twenty":-19.686578,"median":-11.300169,"eighty":-7.572649,"marketCap":37189510},{"date":"2025-03-14","current":-7.381421,"twenty":-19.641554,"median":-11.255905,"eighty":-7.572649,"marketCap":32042747},{"date":"2025-03-21","current":-7.151947,"twenty":-19.630298,"median":-11.225114,"eighty":-7.350824,"marketCap":31046600},{"date":"2025-03-28","current":-7.687386,"twenty":-19.585275,"median":-11.1295,"eighty":-7.412018,"marketCap":33370944},{"date":"2025-04-04","current":-7.242195,"twenty":-19.569517,"median":-10.842657,"eighty":-7.32062,"marketCap":33038895},{"date":"2025-04-11","current":-6.987445,"twenty":-19.454706,"median":-10.555814,"eighty":-7.159596,"marketCap":31876723},{"date":"2025-04-17","current":-7.496946,"twenty":-19.247598,"median":-10.43842,"eighty":-7.190192,"marketCap":34201067},{"date":"2025-04-25","current":-8.006447,"twenty":-18.9662,"median":-10.135111,"eighty":-7.242195,"marketCap":36525412},{"date":"2025-05-02","current":-8.388573,"twenty":-18.90992,"median":-9.982129,"eighty":-7.266684,"marketCap":38268670},{"date":"2025-05-09","current":-7.860875,"twenty":-18.572243,"median":-9.867391,"eighty":-7.314981,"marketCap":35861313}],"updateTime":1747056886469}}}